Zeitschriftenaufsatz | 2025 Open Access

CDK6 kinase inhibition unmasks metabolic dependencies in BCR::ABL1+ leukemia.

Autor:in

Scheiblecker, Lisa; Klampfl, Thorsten; Doma, Eszter; Nebenfuehr, Sofie; Torres-Quesada, Omar; Strich, Sophie; Heller, Gerwin; Werdenich, Daniela; Tschulenk, Waltraud; Zojer, Markus; Bellutti, Florian; Schirripa, Alessia; Zöchbauer-Müller, Sabine; Valent, Peter; Walter, Ingrid; Stefan, Eduard; Sexl, Veronika; Kollmann, Karoline

Publikationen als Autor:in / Herausgeber:in der Vetmeduni

Schirripa, Alessia; Walter, Ingrid; Klampfl, Thorsten; Sexl, Veronika; Kollmann, Karoline; Doma, Eszter

Journal

Cell Death & Disease

Schlagwörter

Humans; Cyclin-Dependent Kinase 6metabolismantagonists & inhibitors; Fusion Proteins, bcr-ablmetabolismgenetics; Glycolysisdrug effects; Protein Kinase Inhibitorspharmacology; Piperazinespharmacology; Cell Line, Tumor; Mitochondriametabolismdrug effects; Apoptosisdrug effects; Oxidative Phosphorylationdrug effects; Cell Proliferationdrug effects; Deoxyglucosepharmacology; Pyridinespharmacology; Leukemia, Myelogenous, Chronic, BCR-ABL Positivemetabolismdrug therapypathologygenetics; Imatinib Mesylatepharmacologytherapeutic use; Drug Resistance, Neoplasmdrug effects; K562 Cells

Dokumententyp

Originalarbeit

CC Lizenz

CCBY

Open Access Type

Gold

ISSN/eISSN

2041-4889 -

DOI

10.1038/s41419-025-07434-1

WoS ID

WOS:001424564200001

PubMed ID

39966356

Repository Phaidra

o:3977

Projekt

ERC ADG: CDK6 in Transkription –vom Feind zum Freund; Linking CDK6 to the epigenome in AML